Senior Partner – Transformation — Patient-Access Organisation

The mandate

An advisory partnership is creating a new Senior Partner seat after boards across European healthcare began asking for transformation support that joins clinical recovery with access, cost and leadership change. Existing teams are strong in isolated disciplines, but no partner consistently carries the whole patient-access problem from board diagnosis to verified operational control. The appointment is urgent because several live opportunities require senior authority.

Approximately 525 employees and material partners sit within the relevant advisory, clinical, data, digital, people and implementation perimeter. The Senior Partner reports to the Global Managing Partner and regional partner council, owning origination, engagement acceptance, client outcomes, risk, economics and senior talent.

The practice will begin with a clear transformation point of view. Patient access is not merely contact-centre productivity or appointment supply. It includes referral completeness, urgency, identity, authorisation, clinical acceptance, scheduling, attendance and follow-up. The Senior Partner will ensure diagnostic work traces cases across these boundaries and identifies where ownership is lost.

Clinical-quality recovery requires humility. Advisers can analyse controls and operating conditions but must not replace authorised clinical judgement. Engagements will include appropriate professional leadership, incident confidentiality and safeguards for speaking up. A transformation plan may propose governance and process change; clinical decisions remain with accountable client officers.

Board origination must be evidence-led. The partner will not promise a percentage cost reduction before understanding demand, risk and workforce. Early conversations should clarify the consequential decision, baseline uncertainty and sponsorship. Work will be declined if the client seeks a predetermined report or lacks authority to act on material findings.

The economics of access are complex. Reducing call time can increase repeat contact; centralising scheduling can remove local pathway knowledge; closing an apparently unproductive queue can displace patients to emergency care. The practice will model total journey cost and patient consequence, making counterfactual assumptions explicit.

Implementation must transfer control. Advisory teams will establish client owners, decision dates, evidence standards and capability from the start. A programme office that remains the only place where the plan is understood is a failed transformation. The Senior Partner will personally review whether leaders can operate routines and explain risk without consultant support.

Digital interventions require adoption and safety evidence. Automation may classify referrals, authenticate patients or offer slots, but errors can become invisible at scale. Teams will test exception paths, cohort outcomes and human override. Benefits will not be counted from licences or releases; they require sustained use and measurable journey change.

Workforce design is part of clinical recovery. Access organisations depend on experienced coordinators, language capability and professional escalation. The Senior Partner will prevent blunt spans or location benchmarks from eliminating scarce knowledge. Where roles change, the plan must include consultation, selection, training and knowledge transfer.

Value assurance will maintain separate measures for harm reduction, access, cost and cash. Avoided harm should not be converted casually into financial benefit. Savings need a baseline, action, owner and ledger consequence. The practice will disclose dependencies and verify outcomes after the initial implementation period.

Engagement risk includes privacy, conflicts and data use. Patient-level case work requires minimum access, secure analysis and defined destruction or return. Serving payers, providers and technology vendors may create ecosystem conflicts beyond the contracting entity. The Senior Partner will make difficult acceptance decisions and protect confidential insights.

The new seat must develop a senior bench. Clinical and technical specialists should progress into client leadership without being used only as delivery support. The partner will sponsor emerging leaders, share board exposure and create transparent credit. Practice growth cannot rely on one individual's network or style.

Zurich will serve as the onsite hub for cross-border work. Regulatory and payer contexts vary; teams must include local expertise and avoid translating one country's waiting-time or productivity model mechanically. The partner will connect regional insight while preserving country truth.

What you will own

• Patient-access and clinical-recovery transformation proposition.
• Board origination and engagement acceptance.
• Diagnostic quality, implementation and value verification.
• Clinical, workforce, digital and economic integration.
• Client ownership transfer and executive capability.
• Privacy, independence and engagement risk.
• Senior talent, account sharing and practice succession.
• Advisory economics and regional reputation.

The first 12 months

Within 45 days, review active pursuits, methods and client risks; establish a case-based access diagnostic and decline or reshape propositions unsupported by evidence. Take direct leadership of priority board conversations.

By month six, launch three board-sponsored transformations with named client owners, independent clinical review and value baselines. Build a cross-functional partner group around the proposition.

At twelve months, secure CHF 70 million of quality-reviewed revenue at target contribution, with at least eight engagements showing verified access or control outcomes. Client leaders should independently operate 90% of implemented routines, and three emerging partners must hold substantive board relationships. No material privacy, independence or clinical-boundary breach is acceptable.

What the council will examine

• Access problems traced across the complete journey.
• Clinical authority respected in recovery work.
• Economic claims separated from safety outcomes.
• Digital benefits proven through adoption and exceptions.
• Client leaders owning the changed operation.
• Practice growth distributed across capable partners.

The person

You bring 28+ years in healthcare transformation, top-tier advisory or senior provider leadership. Your record combines board origination with direct delivery through a quality or access recovery, and includes regulated European markets. You can demonstrate value after implementation rather than at presentation approval.

Candidates need credibility with clinical leaders, governing boards and transformation investors, alongside strong judgement on patient data and conflicts. This onsite Zurich role requires international travel and fluency in cross-border delivery. Market references will be undertaken only through agreed confidential channels.

Compensation and terms

Base compensation is CHF 500,000–700,000 plus annual incentive and long-term participation linked to client outcomes, quality revenue, independent practice, partner development and verified value. The urgent new advisory role is onsite in Zurich and reports to the Global Managing Partner and regional partner council.

Confidentiality

The partnership, clients, patients, engagements, findings, methods and commercial pipeline are confidential. Additional information follows conflicts and signed confidentiality. Applicants must not approach boards, providers or advisers to identify current opportunities or the hiring organisation.